Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 15,621 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Neoplasms
Interventions: PF-06664178; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Seattle, Washington

Conditions: Actinic Keratoses
Interventions: Photodynamic therapy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Sapacitabine, Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Breast Cancer
Interventions: MRI; Procedure
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Rheumatoid Arthritis
Interventions: dnaJ peptide, None-placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 8
States / cities: Tucson, Arizona • Orange, California • Palo Alto, California + 5 more

Conditions: Melanoma (Skin)
Interventions: bleomycin sulfate, electroporation therapy; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Arthritis, Rheumatoid
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 1,712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
Interventions: Lorigerlimab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 11 more

Conditions: Melanoma
Interventions: Educational Intervention, Health Education, Media Campaign, Survey Administration; Other · Behavioral
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 12 Years and older
Enrollment: 75,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Graft vs Host Disease, Sjogren's Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Rheumatoid Arthritis
Interventions: Mailed Arthritis Self-Management Education; Behavioral
Lead sponsor: University of North Carolina; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Peyronie's Disease
Interventions: H-100, Placebo; Drug
Lead sponsor: Hybrid Medical; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Robbinsdale, Minnesota

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
Interventions: Aerobic exercise, Iyengar yoga; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more

Conditions: Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
Interventions: Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study; Biological · Other · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 13
States / cities: San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more

Conditions: Breast Cancer
Interventions: Left Ventricular Ejection Fraction; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 8
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Melanoma
Interventions: Doxycycline, Ipilimumab, Temozolomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pruritus
Interventions: Dupilumab 300Mg Solution for Injection; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
Interventions: Etanercept, Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Duncansville, Pennsylvania • Dallas, Texas

Conditions: Breast Cancer
Interventions: Radiolucent cushion; Device
Lead sponsor: University of Kansas; Other
Eligibility: 40 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Patient Positioning, Monitoring, Physiologic, Pressure Ulcer
Interventions: Zephyr BioPatch; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Isosulfan blue, Axillary Lymph Node Dissection, Surgery, Sentinel Lymph Node Biopsy, Thoracoscopic Surgery, Technetium Tc 99m Sulfur Colloid; Drug · Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Calcinosis Cutis
Interventions: Sodium Thiosulfate, Saline Solution; Drug · Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

A Photodynamic Therapy for Treatment of Actinic Keratoses

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer

dnaJ Peptide for Relieving Rheumatoid Arthritis

Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

MGD019 DART® Protein in Unresectable/Metastatic Cancer

War on Melanoma™ Public Health & Education Campaign

Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells

Development and Evaluation of A Mailed Arthritis Self-Management Program

Peyronie's Disease Treatment Protocol

Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics

Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Effects of Denosumab on the Pharmacokinetics of Etanercept

Use of a Radiolucent Pad to Reduce Mammography Among African Americans

An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis